BP (NYSE: BP ) recently announced it was bailing on its wind power initiatives. The company will sell its U.S. assets, which are spread across nine states and can generate about 2,600 megawatts of power. Estimates place the value of the assets at around $1.5 billion. After getting rid of its solar business, BP is sending a clear message about its commitment to renewables, which may lead investors to consider clean energy investments off-limits for big oil. In this video, Fool.com contributor Aimee Duffy reviews the BP move, and highlights the long-term potential of one oil major who is getting this bet right.
Not all renewable energy investments are created equal. Investors and bystanders alike have been shocked by First Solar's precipitous drop over the past two years. The stakes have never been higher for the company: Is it done for good, or ready for a rebound? If you're looking for continuing updates and guidance on the company whenever news breaks, The Motley Fool has created a brand-new report that details every must know side of this stock. To get started, simply click here now.
Best Clean Energy Stocks To Invest In 2014: Harry Winston Diamond Corporation (HWD)
Harry Winston Diamond Corporation, a diamond company, engages in mining and retailing diamonds in North America, Europe, and Asia. The company supplies rough diamonds through holding a 40% interest in the Diavik Diamond Mine located at Lac de Gras in Canada�s Northwest Territories; and retails fine jewelry and watches under the Harry Winston brand. As of January 31, 2012, it operated 20 directly operated salons, 4 licensed salons, and 194 wholesale watch doors. The company was formerly known as Aber Diamond Corporation and changed its name to Harry Winston Diamond Corporation in 2007. Harry Winston Diamond Corporation was founded in 1980 and is based in Toronto, Canada.
Best Clean Energy Stocks To Invest In 2014: M2 Telecommunications Group Ltd(MTU.AX)
M2 Telecommunications Group Limited provides retail and wholesale fixed line, mobile, and data telecommunications services for small to medium businesses and telecommunications resellers in Australia and New Zealand. Its services include fixed line voice services, including line rental services; mobile voice and data services; and terrestrial dial-up and high speed broadband Internet services, as well as mobile telephone hardware. The company also provides various Internet services, including business broadband ADSL, premium DSL, mobile broadband, BYO mobile broadband, and secure virtual private networks. M2 Telecommunications Group Limited was founded in 1999 and is based in Southbank, Australia.
Top 10 Clean Energy Stocks To Invest In 2014: Intertek Group(ITRK.L)
Intertek Group plc provides quality and safety solutions for a range of industries worldwide. The company operates through five divisions: Commodities, Industry & Assurance, Consumer Goods, Commercial & Electrical, and Chemicals & Pharmaceuticals. The Commodities division provides independent cargo inspection, analytical assessment, and calibration and related research and technical services to the petroleum, mining, minerals, and biofuels industries. This division also provides services to governments and regulatory bodies to support trade activities that enable the flow of goods across borders. The Industry & Assurance division offers a range of services, including asset integrity management, engineering, inspection, auditing, certification, consulting, training, staffing, and testing services. This division serves a range of industries, including oil, gas, petrochemical, power, renewable energy, and civil and infrastructure, as well as provides services to customers in the food and agricultural sectors. The Consumer Goods division provides testing, inspection, auditing, advisory, quality assurance, and hazardous substance testing services to the textiles, toys, footwear, hardlines, and retail industries. The Commercial & Electrical division provides safety, performance and quality testing, and certification services to manufacturers in home appliances, consumer electronics, lighting, medical, building, industrial and heating, ventilation, air conditioning and refrigeration, information communication and technology, renewable energy, and automotive industries. The Chemicals & Pharmaceuticals division provides measurement and consulting services that support business processes, including new drug development, development of new materials, polymers composites, and packaging. This segment serves clients in aerospace, automotive, and pharmaceuticals industries. Intertek Group plc was founded in 1885 and is based in London, the United Kingdom.
Best Clean Energy Stocks To Invest In 2014: Magellan Petroleum Corporation(MPET)
Magellan Petroleum Corporation, together with its subsidiaries, engages in the exploration for, development, production, and sale of oil and gas reserves in Australia, the United States, Canada, and the United Kingdom. Its principal assets include 2 petroleum production leases covering the Mereenie oil and gas field, 1 petroleum production lease covering the Palm Valley gas field, and 1 retention license for the Dingo Field located in the Amadeus Basin in the Northern Territory of Australia; and 13 licenses in the United Kingdom. The company also has a 28.3% working interest in the East Poplar Unit and Northwest Poplar in Montana. Magellan Petroleum Corporation was founded in 1957 and is based in Portland, Maine.
Best Clean Energy Stocks To Invest In 2014: Vicon Industries Inc.(VII)
Vicon Industries, Inc. designs, assembles, and markets video systems and system components for use in security, surveillance, safety, and communication applications. Its product line consists of various elements of a video system, including network/digital/hybrid video recorders, video encoders, decoders, servers and related video management software, data storage units, virtual and analogue matrix video switchers and controls, and system peripherals, as well as analog, high definition, and Internet protocol fixed and robotic cameras. The company?s products are used by commercial and industrial users, such as office buildings, manufacturing plants, warehouses, apartment complexes, shopping malls, and retail stores; federal, state, and local governments for national security purposes, agency facilities, prisons, and military installations; and financial institutions, including banks, clearing houses, brokerage firms, and depositories for security purposes. Its products are also used by gaming casinos; health care facilities, such as hospitals; institutions of education comprising schools and universities; hotels; sports arenas; and transportation departments for highway traffic control, bridge and tunnel monitoring, as well as airport, subway, bus, and seaport security and surveillance. The company sells its products primarily to installing dealers, system integrators, government entities, and distributors principally in the United States, the United Kingdom, rest of Europe, the Middle East, and the Pacific Rim. Vicon Industries, Inc. was founded in 1967 and is headquartered in Hauppauge, New York.
Best Clean Energy Stocks To Invest In 2014: Tvi Pacific Inc Com Npv (TVI.TO)
TVI Pacific Inc. focuses on the acquisition, exploration, production, and development of resource projects in the Philippines. It produces copper and zinc concentrates from its Canatuan mine. The company is also developing the Balabag gold and silver project; and carrying out exploration programs at its Tamarok copper-gold exploration project. It also has interests in an offshore Philippine oil property. TVI Pacific Inc. was incorporated in 1987 and is headquartered in Calgary, Canada.
Best Clean Energy Stocks To Invest In 2014: Lockheed Martin Corporation(LMT)
Lockheed Martin Corporation engages in the research, design, development, manufacture, integration, operation, and sustainment of advanced technology systems and products in the areas of defense, space, intelligence, homeland security, and government information technology in the United States and internationally. It also provides management, engineering, technical, scientific, logistic, and information services. The company operates in four segments: Aeronautics, Electronic Systems, Information Systems & Global Services (IS&GS), and Space Systems. The Aeronautics segment offers military aircraft, including combat and air mobility aircraft, unmanned air vehicles, and related technologies. Its products and programs comprise the F-35 multi-role, stealth fighter; the F-22 air dominance and multi-mission stealth fighter; the F-16 multi-role fighter; the C-130J tactical transport aircraft; and the C-5M strategic airlifter modernization program; and support for the P-3 maritime patrol aircraft, and the U-2 high-altitude reconnaissance aircraft. The Electronic Systems segment provides air and missile defense; tactical missiles; weapon fire control systems; surface ship and submarine combat systems; anti-submarine and undersea warfare systems; land, sea-based, and airborne radars; surveillance and reconnaissance systems; simulation and training systems; and integrated logistics and sustainment services. The IS&GS segment offers information technology solutions and advanced technology primarily in the areas of software and systems integration for space, air, and ground systems to various defense and civil government agencies. The Space Systems segment provides government and commercial satellites; strategic and defensive missile systems, including missile defense technologies and systems, and fleet ballistic missiles; and space transportation systems. Lockheed Martin Corporation was founded in 1909 and is based in Bethesda, Maryland.
Advisors' Opinion:- [By Rich Smith]
Lockheed Martin (NYSE: LMT ) landed a sizable contract award from the U.S. Air Force Thursday, announced as part of the Department of Defense's daily summary of contracts awarded last night.
Best Clean Energy Stocks To Invest In 2014: Sarepta Therapeutics Inc (SRPT)
Sarepta Therapeutics Inc., formerly AVI BioPharma, Inc., incorporated on July 22, 1980, biopharmaceutical company focused on the discovery and development of ribonucleic acid (RNA)-based therapeutics for the treatment of rare and infectious diseases. The Company�� product candidates include Eteplirsen, AVI-6002, AVI-6003, and AVI-7100. As of December 31, 2011, the Company primarily focused on advancing the development of its Duchenne muscular dystrophy drug candidates, including its lead product candidate, eteplirsen, which is in a Phase IIb trial. The Company is also focused on developing therapeutics for the treatment of infectious diseases, including its lead infectious disease programs aimed at the development of drug candidates for the Ebola and Marburg hemorrhagic fever viruses. The Company's program focuses on the development of disease-modifying therapeutic candidates for Duchenne muscular dystrophy (DMD). The Company initiated a Phase IIb trial for eteplirsen in August 2011 with an objective of initiating a pivotal trial subsequent to 2011.
The Company is also leveraging the capabilities of its RNA-based technology platforms to develop therapeutics for the treatment of infectious diseases. The Company's RNA-based drug programs are clinically evaluated for the treatment of DMD and have also demonstrated anti-viral activity in infectious diseases such as Ebola, Marburg and H1N1 influenza in certain animal models. The Company's lead product candidates are at various stages of development.
Duchenne Muscular Dystrophy Program
The Company's lead program is designed to address specific gene mutations that result in DMD by forcing the genetic machinery to skip over an adjacent contiguous piece of RNA and, thus, restore the ability of the cell to express a new, truncated but functional, dystrophin protein.
Eteplirsen is an antisense PMO-based therapeutic in clinical development for the treatment of individuals with DMD who have an error in the gene codi! ng for dystrophin that can be treated by skipping exon 51. Eteplirsen targets the frequent series of mutations that cause DMD. Eteplirsen has been granted orphan drug designation in the United States and European Union. In addition to the Company's lead product candidate, eteplirsen, the Company is actively pursues development of a product candidate that skips exon 45 through an IND-enabling collaboration.
Anti-Viral Programs
The Company is implementing its RNA-based technology platforms in its anti-viral programs for the development of therapeutics to treat viruses, such as Ebola, Marburg and influenza. The Company's arrangement with DoD supporting the development of the Company's Ebola and Marburg virus drug candidates provides funding for all clinical and licensure activities necessary to obtain approval of a New Drug Application (NDA), by the United States Food and Drug Administration (FDA), if DoD exercises all of its options under the arrangement. During the year ended December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and is exploring funding opportunities or partnerships with DHHS and industry collaborators to advance its development.
The Company's anti-viral therapeutic programs use the Company's translation suppression technology and applies its PMOplus chemistry backbone, an advanced generation of its base PMO chemistry backbone that selectively introduces positive backbone charges to improve selective interaction between the drug and its target. The Company's translation suppressing technology is based on Translation Suppressing Oligomers (TSOs), which are PMO-based compounds that stop or suppress the translation of a specific protein by binding to their specific target sequence in mRNA.
The Company is pursuing development and regulatory approval of its Ebola and Marburg hemorrhagic fever virus product candidates under the FDA's Animal Rule. The Company's lead product candidate against the Ebola virus infec! tion is A! VI-6002. For Marburg virus infection, the Company's lead product candidate has been AVI-6003. In February 2012, the Company announced that the Company received approval from the FDA to remove one of the two oligomers composing AVI-6003 and proceed with a single oligomer approach, AVI-7288, given that efficacy in non-human primates has been demonstrated to be attributable to this single oligomer. The Company is exploring the feasibility of alternate routes of administration of its Ebola and Marburg drug candidates, and at DoD's invitation, the Company is developing a proposal to be submitted for a study to demonstrates feasibility of the intramuscular route.
AVI-6002, which is a combination of AVI-7537 and AVI-7539, is designed for post-exposure prophylaxis after documented or suspected exposure to the Ebola virus. The Company is evaluating the feasibility of developing AVI-7537 as a single agent for the post-exposure prophylaxis after documented or suspected exposure to Ebola virus. AVI-6003, which is a combination of AVI-7287 and AVI-7288, is designed for post-exposure prophylaxis after documented or suspected exposure to Marburg virus. In February 2012, the Company announced that the Company received approval from the FDA to proceed with AVI-7288 as a single agent against Marburg virus infection. The Company intends to proceed with dosing AVI-7288 in the Phase I multiple ascending dose studies and in non-human primate studies.
Influenza Program
The Company's anti-viral therapeutic programs are also focused on the development of the Company's product candidates designed to treat pandemic influenza viruses. AVI-7100 is the Company's lead product candidate for the treatment of influenza and employs its PMOplus technology. In June 2011, the Company initiated dosing of AVI-7100 through intravenous infusion in single-ascending doses in up to 48 healthy adult volunteers. As of December 31, 2011, the Company paused its clinical development efforts on AVI-7100 and are exp! loring fu! nding opportunities or partnerships to advance its development.
The Company has developed three new phosphorodiamidate-linked morpholino oligomers (PMO)-based chemistry platforms in addition to its original PMO-based technology. The Company's PMO-based molecules are designed to sterically block the access of cellular machinery to pre-mRNA and mRNA without degrading the RNA. Through this selective targeting, two distinct biologic mechanisms of action can be initiated: modulation of pre-mRNA splicing and inhibition of mRNA translation.
The Company competes with GlaxoSmithKline plc, Toyama Chemical, Alnylam Pharmaceuticals, Inc., Tekmira Pharmaceuticals Corp., Isis Pharmaceuticals, Inc., Prosensa, and Santaris Pharma A/S.
Advisors' Opinion:- [By Keith Speights]
Sarepta Therapeutics (NASDAQ: SRPT ) �won't be the only stock choice for a biotech focusing on Duchenne muscular dystrophy, or DMD, much longer.� Its one potential challenger on the scene, Prosensa, recently announced plans to move forward with an initial public offering. Here are three views on what a Prosensa IPO could mean for Sarepta.
- [By Keith Speights]
Something bold
Buying shares in Sarepta Therapeutics (NASDAQ: SRPT ) requires more boldness from investors than buying J&J stock, but I still think it's a smart idea over the long run. Sarepta is up 33% for the year, but shares have sank nearly 13% in the past few weeks.
No comments:
Post a Comment